[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ff5wXafBi-Isx0OW-x3jQZCP2XZ8IL9F9mTK5csxRqF0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":55,"rows":62},"AdventHealth Translational Research Institute",[4],56,false,30,0,5505,3,46,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Obesity",12,{"name":18,"count":19},"Type 2 Diabetes",8,{"name":21,"count":22},"Diabetes",6,{"name":24,"count":25},"Type 1 Diabetes",4,{"name":27,"count":11},"Aging",{"name":29,"count":11},"Sarcopenia",{"name":31,"count":11},"Metabolic Diseases",{"name":33,"count":34},"Sedentary Behavior",2,[36,41,45,50],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT02817659","To Determine Tolerability to Glucagon Infusion in Obese Subjects","2017-01-13","Glucagon",{"nctId":42,"briefTitle":43,"date":44,"intervention":40},"NCT03139305","Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects","2018-02-14",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05662865","Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers","2024-07-23","SGLT2 inhibitor",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07421518","Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors","2030-04","SGLT-2 inhibitor",[56,57,58,59,60,61],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[63,85,126,147,172,197,215,242,260,278,296,320],{"intervention":54,"totalTrials":64,"cells":65},1,{"EARLY_PHASE1":66,"PHASE1":68,"PHASE2":70,"PHASE3":79,"PHASE4":81,"NA":83},{"trials":67,"activeCount":9},[],{"trials":69,"activeCount":9},[],{"trials":71,"activeCount":64,"soonestReadout":53},[72],{"nctId":51,"briefTitle":52,"status":73,"phases":74,"primaryCompletion":53,"completion":53,"start":75,"enrollment":76,"conditions":77,"interventions":78},"NOT_YET_RECRUITING",[58],"2026-06",75,[24,18],[54],{"trials":80,"activeCount":9},[],{"trials":82,"activeCount":9},[],{"trials":84,"activeCount":9},[],{"intervention":40,"totalTrials":11,"cells":86},{"EARLY_PHASE1":87,"PHASE1":89,"PHASE2":118,"PHASE3":120,"PHASE4":122,"NA":124},{"trials":88,"activeCount":9},[],{"trials":90,"activeCount":34,"soonestReadout":39},[91,99,105],{"nctId":37,"briefTitle":38,"status":92,"phases":93,"primaryCompletion":39,"completion":94,"start":95,"enrollment":96,"conditions":97,"interventions":98},"ACTIVE_NOT_RECRUITING",[57],"2026-12","2016-11-01",20,[15],[40],{"nctId":42,"briefTitle":43,"status":92,"phases":100,"primaryCompletion":44,"completion":101,"start":102,"enrollment":8,"conditions":103,"interventions":104},[57],"2027-02","2017-10-24",[15],[40,40],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":22,"conditions":113,"interventions":115},"NCT02237053","Effects of Glucagon Administration on Energy Expenditure","COMPLETED",[57],"2015-06","2016-06","2014-09",[114,15],"Hyperglucagonemia",[40,116,117],"Octreotide","Insulin",{"trials":119,"activeCount":9},[],{"trials":121,"activeCount":9},[],{"trials":123,"activeCount":9},[],{"trials":125,"activeCount":9},[],{"intervention":49,"totalTrials":64,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":139,"PHASE3":141,"PHASE4":143,"NA":145},{"trials":129,"activeCount":9},[],{"trials":131,"activeCount":64,"soonestReadout":48},[132],{"nctId":46,"briefTitle":47,"status":92,"phases":133,"primaryCompletion":48,"completion":94,"start":134,"enrollment":135,"conditions":136,"interventions":138},[57],"2023-03-16",9,[137],"Ketones, Metabolism",[49],{"trials":140,"activeCount":9},[],{"trials":142,"activeCount":9},[],{"trials":144,"activeCount":9},[],{"trials":146,"activeCount":9},[],{"intervention":148,"totalTrials":64,"cells":149},"Study Medication",{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":154,"PHASE3":166,"PHASE4":168,"NA":170},{"trials":151,"activeCount":9},[],{"trials":153,"activeCount":9},[],{"trials":155,"activeCount":9},[156],{"nctId":157,"briefTitle":158,"status":108,"phases":159,"primaryCompletion":160,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":165},"NCT04432090","GPR119 Agonist for Hypoglycemia in Type 1 Diabetes",[58],"2023-08-12","2021-04-21",110,[164],"Diabetes Mellitus, Type 1",[148],{"trials":167,"activeCount":9},[],{"trials":169,"activeCount":9},[],{"trials":171,"activeCount":9},[],{"intervention":173,"totalTrials":64,"cells":174},"Continous IV infusion of Nesiritide",{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":189,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":176,"activeCount":9},[],{"trials":178,"activeCount":9},[179],{"nctId":180,"briefTitle":181,"status":108,"phases":182,"primaryCompletion":183,"completion":184,"start":185,"enrollment":22,"conditions":186,"interventions":187},"NCT03234751","Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects",[57],"2018-09-24","2020-02-19","2017-07-13",[21],[173,188],"Hyperinsulinemic euglycemic clamp",{"trials":190,"activeCount":9},[],{"trials":192,"activeCount":9},[],{"trials":194,"activeCount":9},[],{"trials":196,"activeCount":9},[],{"intervention":188,"totalTrials":64,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":207,"PHASE3":209,"PHASE4":211,"NA":213},{"trials":200,"activeCount":9},[],{"trials":202,"activeCount":9},[203],{"nctId":180,"briefTitle":181,"status":108,"phases":204,"primaryCompletion":183,"completion":184,"start":185,"enrollment":22,"conditions":205,"interventions":206},[57],[21],[173,188],{"trials":208,"activeCount":9},[],{"trials":210,"activeCount":9},[],{"trials":212,"activeCount":9},[],{"trials":214,"activeCount":9},[],{"intervention":216,"totalTrials":64,"cells":217},"Nesiritide",{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":234,"PHASE3":236,"PHASE4":238,"NA":240},{"trials":219,"activeCount":9},[],{"trials":221,"activeCount":9},[222],{"nctId":223,"briefTitle":224,"status":108,"phases":225,"primaryCompletion":226,"completion":227,"start":228,"enrollment":25,"conditions":229,"interventions":232},"NCT01977859","BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects",[57],"2016-02-15","2017-02-28","2013-11",[15,230,231,21],"Cardiovascular Disease","Hypertension",[216,233],"Saline",{"trials":235,"activeCount":9},[],{"trials":237,"activeCount":9},[],{"trials":239,"activeCount":9},[],{"trials":241,"activeCount":9},[],{"intervention":233,"totalTrials":64,"cells":243},{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":252,"PHASE3":254,"PHASE4":256,"NA":258},{"trials":245,"activeCount":9},[],{"trials":247,"activeCount":9},[248],{"nctId":223,"briefTitle":224,"status":108,"phases":249,"primaryCompletion":226,"completion":227,"start":228,"enrollment":25,"conditions":250,"interventions":251},[57],[15,230,231,21],[216,233],{"trials":253,"activeCount":9},[],{"trials":255,"activeCount":9},[],{"trials":257,"activeCount":9},[],{"trials":259,"activeCount":9},[],{"intervention":116,"totalTrials":64,"cells":261},{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":270,"PHASE3":272,"PHASE4":274,"NA":276},{"trials":263,"activeCount":9},[],{"trials":265,"activeCount":9},[266],{"nctId":106,"briefTitle":107,"status":108,"phases":267,"primaryCompletion":110,"completion":111,"start":112,"enrollment":22,"conditions":268,"interventions":269},[57],[114,15],[40,116,117],{"trials":271,"activeCount":9},[],{"trials":273,"activeCount":9},[],{"trials":275,"activeCount":9},[],{"trials":277,"activeCount":9},[],{"intervention":117,"totalTrials":64,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":288,"PHASE3":290,"PHASE4":292,"NA":294},{"trials":281,"activeCount":9},[],{"trials":283,"activeCount":9},[284],{"nctId":106,"briefTitle":107,"status":108,"phases":285,"primaryCompletion":110,"completion":111,"start":112,"enrollment":22,"conditions":286,"interventions":287},[57],[114,15],[40,116,117],{"trials":289,"activeCount":9},[],{"trials":291,"activeCount":9},[],{"trials":293,"activeCount":9},[],{"trials":295,"activeCount":9},[],{"intervention":297,"totalTrials":64,"cells":298},"BPM31510",{"EARLY_PHASE1":299,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":318},{"trials":300,"activeCount":9},[301],{"nctId":302,"briefTitle":303,"status":304,"phases":305,"primaryCompletion":306,"completion":306,"start":307,"enrollment":9,"conditions":308,"interventions":309},"NCT04999488","Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia","WITHDRAWN",[56],"2024-12","2023-12",[29],[297],{"trials":311,"activeCount":9},[],{"trials":313,"activeCount":9},[],{"trials":315,"activeCount":9},[],{"trials":317,"activeCount":9},[],{"trials":319,"activeCount":9},[],{"intervention":321,"totalTrials":64,"cells":322},"Phentermine",{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":333},{"trials":324,"activeCount":9},[],{"trials":326,"activeCount":9},[],{"trials":328,"activeCount":9},[],{"trials":330,"activeCount":9},[],{"trials":332,"activeCount":9},[],{"trials":334,"activeCount":9},[335],{"nctId":336,"briefTitle":337,"status":108,"phases":338,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":344},"NCT01616082","Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)",[61],"2012-11","2011-09",39,[15,343,31],"Overweight",[321]]